Show simple item record

dc.contributor.authorMalty, Ramy H.en_US
dc.contributor.authorJessulat, Matthewen_US
dc.contributor.authorJin, Keen_US
dc.contributor.authorMusso, Gabrielen_US
dc.contributor.authorVlasblom, Jamesen_US
dc.contributor.authorPhanse, Sadhnaen_US
dc.contributor.authorZhang, Zhaoleien_US
dc.contributor.authorBabu, Mohanen_US
dc.date.accessioned2015-12-04T18:13:28Z
dc.date.issued2014en_US
dc.identifier.citationMalty, Ramy H., Matthew Jessulat, Ke Jin, Gabriel Musso, James Vlasblom, Sadhna Phanse, Zhaolei Zhang, and Mohan Babu. 2014. “Mitochondrial Targets for Pharmacological Intervention in Human Disease.” Journal of Proteome Research 14 (1): 5-21. doi:10.1021/pr500813f. http://dx.doi.org/10.1021/pr500813f.en
dc.identifier.issn1535-3893en
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:23845191
dc.description.abstractOver the past several years, mitochondrial dysfunction has been linked to an increasing number of human illnesses, making mitochondrial proteins (MPs) an ever more appealing target for therapeutic intervention. With 20% of the mitochondrial proteome (312 of an estimated 1500 MPs) having known interactions with small molecules, MPs appear to be highly targetable. Yet, despite these targeted proteins functioning in a range of biological processes (including induction of apoptosis, calcium homeostasis, and metabolism), very few of the compounds targeting MPs find clinical use. Recent work has greatly expanded the number of proteins known to localize to the mitochondria and has generated a considerable increase in MP 3D structures available in public databases, allowing experimental screening and in silico prediction of mitochondrial drug targets on an unprecedented scale. Here, we summarize the current literature on clinically active drugs that target MPs, with a focus on how existing drug targets are distributed across biochemical pathways and organelle substructures. Also, we examine current strategies for mitochondrial drug discovery, focusing on genetic, proteomic, and chemogenomic assays, and relevant model systems. As cell models and screening techniques improve, MPs appear poised to emerge as relevant targets for a wide range of complex human diseases, an eventuality that can be expedited through systematic analysis of MP function.en
dc.language.isoen_USen
dc.publisherAmerican Chemical Societyen
dc.relation.isversionofdoi:10.1021/pr500813fen
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286170/pdf/en
dash.licenseLAAen_US
dc.subjectReviewsen
dc.subjectDrug−protein interactionsen
dc.subjecthuman diseaseen
dc.subjectmitochondriaen
dc.subjectmodel systemen
dc.subjectnetworken
dc.subjectpharmacological targeten
dc.subjectprotein complexen
dc.subjectpathwaysen
dc.subjectsmall moleculesen
dc.subjectsystems biologyen
dc.titleMitochondrial Targets for Pharmacological Intervention in Human Diseaseen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalJournal of Proteome Researchen
dc.date.available2015-12-04T18:13:28Z
dc.identifier.doi10.1021/pr500813f*


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record